Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2020

View Archived Issues

Greenwich LifeSciences presents phase IIb data for cancer vaccine GP-2/GM-CSF

Oncolytic virus combines best of both immune worlds

Rule-based screening for degraders

Activity profiling and crystal structures to guide the design of SARS-CoV-2 PLpro inhibitors

RGFP-963 demonstrates promise in mouse models of ALS

Phase I and II clinical data reported for human IL-12 gene therapy Ad-RTS-hIL-12

HDAC6 inhibition as potential new therapeutic strategy for ALS

Prothena reports positive 9-month data from phase I study of PRX-004

Positive topline data presented from phase Ib study of EDP-1815 in atopic dermatitis

Bristol-Myers Squibb discovers Nuclear receptor ROR-gammaT agonists

New aryl hydrocarbon receptor antagonists disclosed by Antidote IP Holdings

Dana-Farber Cancer Institute patents focal adhesion kinase inhibitors

New Na(+)/H(+) exchanger 3 inhibitors identified at Lilly

DMC issues recommendation regarding global phase III study of PLX-PAD in CLI

Senju Pharmaceutical describes PAC1/VPAC1/VPAC2 receptor ligands

New preclinical data confirms efficacy of apelin agonists in ARDS

Dosing initiates in phase I study of ALT-801 for the treatment of NASH

Resolve presents positive phase IIa data for RSLV-132 in patients with SLE

Activity seen with ZEN-003694 plus talazoparib in metastatic triple-negative breast cancer

Phase III VIOLET studies of oteseconazole for recurrent VVC meet primary endpoint

SABCS2020: Verzenio continues to show benefit, but time may topple monarchE

First phase III induction study with upadacitinib in ulcerative colitis meets primary endpoint

Applied Therapeutics reports MRS data on reduction of galactitol levels with AT-007 for galactosemia

ObsEva reports further phase III data on use of linzagolix for bleeding due to uterine fibroids

Editas submits IND for EDIT-301 for sickle cell disease

Cytokinetics advances phase II trial of CK-3773274 for symptomatic obstructive HCM

Rocket reports preliminary phase I data on RP-A501 for Danon disease

Week 48 data reported from phase III PEGASUS trial of pegcetacoplan in PNH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...